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INTRODUCTION 
Hyponatremia is the most common electrolyte abnormality seen in 
hospitalised patients and is also the most common electrolyte imbalance seen in 
critically ill neurologic patients. It can significantly alter the morbidity, short 
and long term mortality of the underlying disease.  
The causes of hyponatremia are varied, but in neurologically ill patients, 
are most commonly attributed to Syndrome of Inappropriate Anti-diuresis and 
Cerebral Salt Wasting. Both these entities are cerebral in origin but have 
distinct pathophysiology, prognosis and treatment options. The importance of 
distinguishing both lies in the fact that the therapy indicated for one if used for 
the other, can be deleterious. 
Distinction between the two requires a battery of investigations since 
there is considerable overlap between the two conditions, and no single 
parameter can define either entity.  
SIADH is a subclinically volume expanded state due to inappropriate 
anti-diuresis. This causes excessive volume overload over the body sodium 
content leading onto euvolemic hyponatremia. In stroke SIADH occurs due to 
AVP secretion inappropriate to the osmotic threshold. The suppressed proximal 
renal tubular transport in this condition can lead on to bicarbonaturia and 
hypouricemia. The effective treatment is fluid restriction. Hypertonic saline 
therapy is reserved for cases of severe hyponatremia. 
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CSW, on the other hand, is essentially a volume depleted state, which 
occurs due to the combined effects of decreased sympathetic outflow and 
increased natriuretic peptides. This resultant natriuresis leads to volume 
depletion and an appropriate AVP response. So the treatment for CSW includes 
an aggressive volume replacement regimen with isotonic saline or in severe 
cases, hypertonic saline.  
Thus most CSW patients meet the criteria for SIADH and have elevated 
AVP levels but worsen with the treatment protocol given for SIADH. This 
observation lead to the description of CSW as a separate entity and widespread 
studies were carried out to distinguish the two entities.  
At present the two entities are differentiated using combined analysis of 
sodium levels, plasma osmolality, uric acid, effective arterial blood volume, 
urine sodium, serum potassium, haematocrit, BUN/creatinine ratio. 
Hyponatremia, especially Cerebral Salt Wasting, occurring in the setting 
of stroke has been shown to worsen the prognosis of stroke, increase morbidity, 
short and long term mortality, and cause a poorer discharge disposition. 
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AIMS AND OBJECTIVES 
 
• To study the prevalence of hyponatremia in the setting of acute stroke 
 
• To  distinguish between SIADH and CSW among hyponatremic patients 
 
 
• To study the implication of SIADH and CSW on the short term outcome 
of stroke. 
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REVIEW OF LITERATURE 
The consequences of salt depletion was first described by Mc Cance in 
1936 [1].  
 In 1950, Peters et al [2] at Yale described three neurologic patients with 
hyponatremia.  Both patients had increased urine sodium loss and dehydration 
in spite of high sodium diet. In 1952, Cort [3] in Yale described another similar 
patient as having Cerebral salt wasting syndrome.  
In1953,Leaf et al[4] demonstrated that giving exogenous vasopressin 
caused hyponatremia and natriuresis. He described this to be a physiologic 
response to increased intra-vascular volume.  
Schwartzet al [5] published the paper on SIADH which became a 
milestone. For over two decades the term CSW vanished from literature. In 
1981,Nelson et al [6] reintroduced the term based on his findings in patients 
with sub-arachnoid haemorrhage, finding volume contraction in those patients 
in spite of hyponatremia. 
Further correlations between hyponatremia in subarachnoid 
haemorrhage with increased levels of natriuretic peptides, negative sodium 
balance,[7], [8] and low central venouspressure[9] were published. 
SODIUM AND WATER REGULATION 
The interactions between the kidney and the brain play an important role 
in the sodium and water homeostasis. 
5 
 
Arginine vasopressin or the Anti-diuretic hormone is the key hormone 
and is synthesised in a precursor form in the magnocellular neurons of the 
supra-optic and paraventricular nuclei in the hypothalamus. From the 
hypothalamus it is transported by axonal transport to the neurohypophysis in 
the pituitary and is cleaved to the active form and secreted into the blood. 
Disorders of sodium balance are due to disorders in regulation of water 
balance. Defects in water intake and Arginine vasopressin levels are the major 
effectors of plasma osmolality. This would in turn affect the sodium levels. 
HYPONATREMIA 
 Hyponatremia is the most common electrolyte disturbance in neurologic 
patients [10]Hyponatremia is defined as sodium level of less than 130 meq/L 
and occurs in 20% of hospitalised patients [11] and the in-hospital mortality 
rate is found to be 1.5 fold higher than those with normal sodium levels [12]. 
Water and sodium homeostasis are tightly regulated and thus 
disturbances in water homeostasis can lead onto sodium imbalance. 
Sodium being the major extracellular ion is the principal determinant of 
serum osmolality. Thus the interplay between circulating vasopressin and water 
intake plays a key role in regulating the serum osmolality. Relative sodium 
concentration thus changes with water homeostasis and hence absolute plasma 
sodium values do not suffice to tell about the volume status of the patient. 
Hyponatremia is a very common disorder occurring in upto 22% of inpatients.  
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The main mechanisms responsible include  
1) Increase in circulating Vasopressin 
2) Increased renal sensitivity to AVP 
3) Low solute intake 
Based on the underlying pathophysiology, hyponatremia may be 
Euvolemic, Hypovolemic or Hypervolemic 
HYPOVOLEMIC HYPONATREMIA 
Hypovolemia 
Neurohumoral activation 
Increased circulating Vasopressin levels 
1) V1A receptor mediated blood pressure maintenance 
2) V2 receptor mediated free water reabsorption 
Hypovolemic hyponatremia may be caused through 
1) Renal losses like RTA, diuretic usage, ketonuria, osmotic dieresis and 
rarely cerebral salt wasting syndrome.In renal losses, there is excessive loss of 
solute from the body and hence an appropriate rise of circulating AVP occurs. 
Salt losing nephropathies typically lead to hyponatremia in the setting of a 
reduced sodium intake. Causes of salt losing nephropathies include reflux 
nephropathy, medullary cystic disease, post-obstructive uropathy and the 
recovery phase in Acute Tubular Necrosis. 
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Thiazide diuretics cause not only diuretic induced volume depletion but 
can also cause polydipsia. Increased excretion of an osmotically active agent 
like ketonuria, glycosuria, mannitol administration and bicarbonaturia. 
2) Non- renal losses like third space fluid loss like pancreatitis, GI losses  
like vomiting or diarrhoea, insensible loss like burns 
In renal losses, urinary sodium measures > 20 mM whereas in non renal losses 
the urinary sodium tends to remain < 20 mM. 
HYPERVOLEMIC HYPONATREMIA 
This is characterised by an increase in the the total body sodium content 
and an inappropriately greater increase in the total body water. The different 
causative mechanisms can be differentiated by the urinary sodium 
concentration with acute or chronic renal failure causing increased urinary 
sodium, and cirrhosis, cardiac failure causing decreased urinary sodium 
excretion. The degree of hyponatremia serves as an indirect measure of the 
degree of neuro-humoral activation and hence serves as an important 
prognostic factor. 
EUVOLEMIC HYPONATREMIA 
Conditions leading onto increased total body water in the setting of a 
normal sodium concentration result in euvolemic hyponatremia. 
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Causes of euvolemic hyponatremia: 
1) Moderate to severe hypothyroidism which is corrected once euthyroid state 
is achieved 
2) Pituitary disease causing secondary adrenal insufficiency due to a 
predominant glucocorticoid deficient state. In contrast, primary adrenal 
insufficiency, causing aldosterone deficiency, leads on to hypovolemic 
hyponatremia.  
 Glucocorticoids exert a negative feedback on vasopressin release in such an 
effective manner, that hydrocortisone replacement can rapidly normalise the 
circulating AVP, correcting the sodium imbalance. 
3) The Syndrome of Inappropriate Anti-diuresis is the most frequent cause of 
euvolemic hyponatremia. In SIADH the osmotic threshold and the osmotic 
response curves are shifted downward. The precipitation of hyponatremia is 
by excessive free water intake at serum osmotic values lesser than the 
normal threshold. 
Patterns of SIADH- 
Four distinct patterns of SIADH are known to occur 
1) Unregulated erratic AVP secretion- seen in one-third of the patients, 
where the AVP secretion does not correlate with the serum osmolality. 
2) Failure of suppression of AVP secretion at lower serum osmolalities with 
a normal response to hyperosmolar conditions.  
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3) Resetting of the osmostat – causing lowering of the osmotic threshold 
and left shift of the osmotic response curve. 
4) Gain in function of renal water reabsorption or a circulating anti-diuretic 
substance apart from vasopressin. A gain of function mutation of the V2 
AVP receptor in the collecting tubule has been described. This could lead to 
constitutive activation of the V2 AVP receptor even in the absence of AVP 
and hence leads on to Nephrogenic SIADH. 
SIADH patients are not euvolemic but have a subclinically expanded 
body volume. This volume expansion is due to vasopressin mediated water 
and sodium chloride retention. In SIADH, there is increased distal sodium 
and water transport and this leads to a supressed proximal tubular 
reabsorption and thus leading to low serum uric acid levels (<4 mg/dl), in 
contrast in patients with hypovolemic hyponatremia, there is hyperuricemia 
due to shared activation of proximal tubule sodium-chloride and urate 
transport.SIADH is caused by a variety of diseases, the common causes of 
which include pneumonia, tuberculosis, pleural effusion, tumor, 
subarachnoid haemorrhage, meningitis. It can also occur as a para-
neoplastic condition as in small cell carcinoma of the lung, attributing to 
75% of the malignancy associated SIADH. Upto 10% of the patients with 
this tumor are found to have sodium levels of< 130mM during initial 
presentation. 
SIADH is also frequently caused by drugs like Selective Serotonin 
Reuptake Inhibitors.  
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Other drugs can cause SIADH by causing enhanced sensitivity to the 
circulating vasopressin, and they include 
Chlorpropamide 
Tricyclic antidepressants 
Clofibrate 
Carbamazepine 
Vincristine 
Nicotine 
Narcotics 
Ifosfamide 
MDMA- can cause acute hyponatremia 
Desmopressin 
Oxytocin 
Vasopressin  
Hyponatremia due to low solute intake- 
Commonly seen due to beer potomania, beer having a low salt and 
protein content (1-2mM of sodium) and excessive beer intake can caue 
hyponatremia.  
It has also been described in people eating extreme vegetarian diets and 
other nutrient restricted diets.  
These patients typically present with a very low urine osmolality (< 100- 
200 mOsm/kg) and a urine sodium of < 10-20 mM. The reduced urinary 
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sodium excretion will also limit water excretion thus causing volume expansion 
and thus hyponatremia occurs in the setting of modest polydipsia. Resumption 
of a normal diet rich in solute or saline hydration would correct the 
hypovolemia due to low solute intake.  
CLINICAL FEATURES OF HYPONATREMIA 
                                       Hyponatremia 
 
                              Water movement ECF       ICF 
 
                                Generalised cellular swelling 
 
                                             Cerebral Edema 
 
                                        Neurologic Symptoms 
 
ACUTE HYPONATREMIA 
 
Increased interstitial pressure 
 
Shunting of water and solutes into CSF 
 
Shunting into systemic Circulation 
 
Efflux of Na+, K+ and Cl- from brain cells 
 
Hyponatremic encephalopathy 
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Acute hyponatremia is a medical emergency and can result in 
normocapneic or hypercapneic respiratory failure, seizures, brain stem 
herniation, coma and death. 
CAUSES OF ACUTE HYPONATREMIA 
Iatrogenic- post operative  
Hypotonic fluid therapy causing increased AVP 
Glycine irrigation- during TURP/ Uterine surgery 
Colonoscopy Preparation 
Recent thiazide use 
Polydipsia 
MDMA intake 
Exercise   
Multifactorial causes 
CHRONIC HYPONATREMIA 
Chronic persistent hyponatremia 
 
Efflux of organic osmolytes from brain cells 
      
Decreased intracellular osmolality 
 
Water influx down the osmotic gradient into the cells 
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Chronic hyponatremia can still result in some amount of nausea, 
vomiting, confusion, and seizures especially when levels fall below 125mM 
At times the patient may manifest only with subtle gait defects, 
increased fall risk and cognitive defects that are reversible with sodium 
correction. 
During correction of hyponatremia, the the re-accumulation of the brain 
osmolytes as the osmolality rises is delayed and this could result in 
degeneration of oligodendrocytes and hence demyelination. This is especially 
marked during rapid correction and there is also a disruption of the blood brain 
barrier and entry of immune mediators, contributing to the demyelination. The 
classical region affected is pons where the re-accumulation of osmolytes is 
markedly delayed. Clinically, the patients may present after 1 or more days 
with paraparesis, quadriparesis, ‘locked-in syndrome’ or coma.   
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Approach to a neurologic patient with hyponatremia  
 
Fig.1 THE GENERAL APPROACH TO THE HYPONATREMIC 
PATIENT 
 
Cerebral salt wasting (CSW) and the syndrome of inappropriate 
antidiuretic hormone secretion (SIADH) can be differentiated most 
effectively by assessment of the volume status of the patient. 
Abbreviations: ECF, extracellular fluid volume; EABV, effective 
arterial blood volume. 
 
 
Serum osmolality 
Pseudohyponatremia 
Hyperglycemia 
Urine osmolality 
Primary polydipsia 
Beer potomania syndrome 
EABV 
ECF volume 
Cerebral salt wasting 
Diarrhea 
Diuretics 
Mineralocorticoid deficiency 
Edematous states 
SIADH 
Glucocorticoid deficiency 
Hypothyroidism 
Drugs 
Inappropriately high 
Decreased Normal 
Appropriately low 
Normal Low 
High Low 
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Hyponatremia  in  the  setting  of  central  nervous  system diseases  
occur commonly  in  two  patterns-   
1. Syndrome of Inappropriate Anti- Diuretic Hormone  secretion  and   
2. Cerebral Salt Wasting 
due to interaction between the brain and kidneys [21] 
SYNDROME OF INAPPROPRIATE ANTI- DIURETIC HORMONE  
SECRETION  
SIADH is a volume-expanded state 
In SIADH, there is 
1) Inappropriate increase in ADH secretion which leads to an increased EABV. 
2) downward resetting of the osmotic thirst threshold  
leading on to a volume expanded state 
As  shown  by  studies  of  exogenous  pitressin  administration [4]  to  
normal  population, excess  of  vasopressin  increases  water  retention  and  
thus  leads  to  an  abrupt  decrease  in  urine  volume   and  increased  urine  
osmolality, and  leads  to  an  increase  in  body  weight  and  hyponatremia.   
After   several  days,   a  steady  state  is  reached  and  sodium  
excretion  becomes  equal  to  dietary  sodium intake.  This  is  attributed  to  
the  vasopressin escape phenomenon [22] causing  decreased  proximal  sodium  
reabsorption. 
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During  this  steady  state,  large  isotonic  sodium  load  could  lead  to  
a  quantitatively  similar  urinaryexcretion  of  sodium. [23]   This  shows  that  
a  normal  renal  handling  in  spite  of  decreased  serum  sodium  is  a 
characteristic  in  SIADH.  
In SIADH, ECF expansion  is  not  accompanied   by  overt  signs  of  
hypervolemia  like neck  vein  distension  or  peripheral edema,  but  has  
increased  GFR  and  increased  renal  blood  flow. Due  to  decreased  
proximal  tubular  reabsorption,  uric  acid  and  urea,  both  of  which  are  
proximally  reabsorbed, are also  seen  to  decrease  in  blood  [24] 
Essential feature 
Decreased effective osmolality (<275 mOsm/kg of water) 
Urinary osmolality >100 mOsm/kg of water during hypotonicity 
Clinical euvolemia 
No clinical signs of volume depletion of extracellular fluid 
No orthostasis, tachycardia, decreased skin turgor, or dry mucous membranes 
No clinical signs of excessive volume of extracellular fluid No edema or 
ascites 
Urinary sodium >20 mEq/L with normal dietary salt intake 
Normal thyroid and adrenal function 
No recent use of diuretic agents 
Plasma uric acid <4 mg/dL 
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Blood urea nitrogen <10 mg/dL 
Fractional sodium excretion >1%; fractional urea excretion >55% 
Failure to correct hyponatremia after 0.9% saline infusion 
Correction of hyponatremia through fluid restriction Abnormal result on test 
of water load (<80% excretion of 20 mL of water per kilogram of body 
weight over a period of 4 hours), or inadequate urinary dilution (<100 
mOsm/kg of water) 
Elevated plasma AVP levels, despite the presence of hypotonicity and 
clinical euvolemia 
 
 
FIG 2- DIAGNOSTIC CRITERIA FOR SIADH [25] 
Encephalitis (viral or bacterial) Cavernous sinus thrombosis 
Meningitis (viral, bacterial, 
tuberculosis, fungal) Neonatal hypoxia 
Traumatic brain injury Hydrocephalus 
Brain abscess Delirium tremens 
Brain tumors Cerebrovascular accident 
Guillain-Barré syndrome Acute psychosis 
Acute intermittent porphyria Peripheral neuropathy 
Subarachnoid hemorrhage  Multiple sclerosis 
Subdural hematoma 
Cerebellar and cerebral atrophy 
Any kind of surgery, most notably 
transsphenoidal pituitary surgery 
 
 
Fig 3- NEUROLOGIC DISEASES COMMONLY ASSOCIATED WITH 
SIADH 
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CEREBRAL SALT WASTING 
The recognition of a distinct subset of hyponatremic patients having 
hypovolemia in spite of meeting the criteria of SIADH, lead to the discovery of 
Cerebral Salt Wasting. Wijdicks et al. [26] showed the development of a 
condition similar to SIADH in SAH patients but had a 10% decrease in plasma 
volume. He also found that a negative sodium balance preceeded the condition.  
Levine et al. [27] showed hyponatremia and volume depletion in ten 
craniosynostosis post- operative patients in spite of intravenous fluid 
administration to match sodium output.  
CSW is a volume-depleted state hypothesised to be due to decreased 
sympathetic nervous system outflow in patients with a CNS insult. Also shown 
to be implicated are increased levels of natriuretic factors like atrial natriuretic 
peptide and brain natriuretic peptide. 
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Pathophysiology of CSW 
 
Fig 4. PATHOPHYSIOLOGY OF CEREBRAL SALT WASTING 
SYNDROME. 
 
BNP, brain natriuretic peptide; RAS, rennin angiotensin system; AVP,   
Arginine vasopressin; GFR, glomerular filtration rate 
Decreased sympathetic input to the kidney causes  
1) Alteration in the sodium and water handling of the proximal tubule 
2) Failure of rise in renin and aldosterone levels in response to hyponatremia[ 
28, 29] 
Increased natriuretic peptides can 
1) Increase GFR by dilatation of afferent and constriction of efferent renal 
arterioles 
2) Cause direct inhibition of sodium reabsorption from inner medullary 
cortical duct [30] 
 
 
Brain 
Kidney 
Sympathetic outflow↓ 
Natriuretic peptides↑  
( especially BNP ) 
Proximal Sodium reabsorption↓ 
RAS inactivation 
Vasorelaxant: GFR↑ 
IMCT Sodium reabsorption↓ 
AVP antagonism: water reabsorption ↓ 
• 
Natriuresis 
• 
Volume depletion 
• 
Appropriate AVP secretion  
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3) Direct inhibition of renin release in the juxta glomerular apparatus 
4) Inhibition of aldosterone release from the adrenal glands 
5) Decrease sympathetic outflow from the brain stem 
 
Increased natriuretic peptides especially BNP has been proved by Berendes 
et al [29].Patients with SAH who underwent aneurysmal clipping were 
compared with controls of patients undergoing craniotomy for brain tumor 
resection. After a three to four day duration, the SAH group had a peak 
increase of urine sodium excretion and correlated with increased BNP levels. 
The BNP levels also correlated with intracranial pressure and with the level of 
urine sodium excretion. 
The volume depletion in CSW activates baroreceptors thereby 
stimulating increased Anti-diuretic hormone secretion and hence patients with 
CSW also show increased ADH levels.    
The incidence is found to be 34% in aneurysmal SAH patients [13] and 
70% in tuberculous meningitis [14] and 35.3% in stroke[15] and 25-35% after 
trans sphenoidal surgeries [16, 17]  
DIFFERENCES BETWEEN SIADH AND CSW 
Differentiating between the two entities is of utmost importance due to 
the varied prognostic and treatment options between them. 
Differentiation can be difficult due to an overlap of laboratory 
parameters between the two entities. 
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 The primary difference lies in the effective arterial blood volume 
(EABV), which is increased in SIADH and vice versa in CSW. Since EABV is 
a clinical entity it can only be indirectly measured by levels of urine sodium 
excretion and ECF volume. Thus the differentiation of SIADH and CSW 
requires a panel of physical and laboratory investigations. 
Physical features: 
 SIADH shows features of normal to increased ECF volume whereas 
 CSW shows dry skin and mucosa , orthostasis, flat neck veins, and a 
negative fluid balance [11] 
Laboratory features: 
 CSW SIADH 
Extracellular fluid volumeb Decreased Increased 
Hematocrit Increased Normal 
Plasma albumin concentration Increased Normal 
Plasma BUN/creatinine Increased Decreased 
Plasma Kþ Normal or 
increased 
Normal 
Plasma uric acid Decreased Decreased 
Treatment Normal saline Fluid restriction 
 
 
Fig 5. DIFFERENTIATION BETWEEN SIADH AND CSW [11] 
 
 Determination of extracellular fluid volume is the primary way to 
differentiate CSW from SIADH. 
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 Serum uric acid is a special tool in SIADH and CSW differentiation. It 
initially tends to be low in both [31, 32], being inappropriately low in CSW. On 
correction of sodium levels, it tends to normalise in SIADH whereas it remains 
abnormally low in CSW patients [31] due probably to prolonged proximal 
tubule dysfunction [31,33] 
TREATMENT OF SIADH vs CSW 
 The treatment modalities widely vary for SIADH and CSW and it is 
important to distinguish between the two since inappropriate treatment can 
result in an adverse outcome.  
 In CSW, fluid restriction can worsen the already volume depleted state 
and can worsen the underlying neurologic problem.   
 Wijdicks et al. [34] showed the development of delayed cerebral 
infarction in 21 on 44 SAH patients who were treated with fluid restriction 
though 15 of these patients satisfied SIADH criteria. This was later attributed 
to possible CSW. The decreased plasma volume in conjunction with the 
vasospasm in SAH could have been the causative of delayed cerebral 
infarction.  
 Thus in CSW aggressive salt and fluid replacement is necessary to 
maintain intravascular volume 
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 Intravenous saline (isotonic or hypertonic), salt tablets or agent with 
mineralocorticoid activity like fluodrocortisone are the various treatment 
options [35, 36] 
 On the other hand, SIADH requires fluid restriction as the treatment. 
 Intravenous saline given in this volume-expanded state could lead to 
symptomatic hyponatremia, and worsening clinical condition.  
 So the osmolality of the administered fluid should exceed the osmolality 
of urine [11]. 
 More targeted therapies would include AVP receptor antagonists [37] 
 The other treatment options would include drugs like frusemide, 
demeclocycline and lithium. 
 Patients with acute sodium reductions and severe neurologic symptoms 
may need initial rapid sodium correction with hypertonic saline, but caution is 
necessary to prevent against osmotic demyelination during correction [38,39] 
CEREBROVASCULAR ACCIDENT 
 Stroke is the second leading cause of death worldwide. The number of 
deaths due to stroke was 6.2 million in 2011.The number of stroke cases is 
projected to increase as the elderly population grows.  
 Stroke is defined as an abrupt onset of a neurologic deficit that is 
attributable to a focal vascular cause. Thus stroke is a clinically defined entity, 
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brain imaging and laboratory tests serving to be supportive to the diagnosis.The 
complex brain structure and vasculature are the reasons for the wide variability 
of clinical manifestations.  
ISCHEMIC STROKE 
 A reduction of perfusion lasting longer than a few seconds suffices to 
cause cerebral ischemia, and overt neurologic symptoms manifest.This is 
mainly attributable to absent glycogen stores in the brain tissue. A cessation of 
blood flow lasting in minutes can cause brain infarction. A quick restoration of 
blood flow can cause full recovery of brain tissue and thus only transient 
symptoms, thus leading onto transient ischemic attack.  Stroke is defined to 
have occurred when neurologic symptoms persist for more than 24 hours or if 
there is imaging evidence of infarction  
 A generalised blood flow compromise due to systemic hypotension can 
initially cause syncope. Persistent hypotension causes infarction at the 
borderline areas between the major blood vessel territories, called water-shed 
infarcts. 
  In more severe cases, global hypoxia- ischemia can result in diffuse brain 
injury and hypoxic ischemic encephalopathy. 
  Focal ischemia results from thrombosis or emboli in the arteries. 
  Intracranial haemorrhage is caused by bleeding into the brain 
parenchyma or in the surrounding region. The symptoms in hemorrhagic stroke 
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can result from mass effect of the surrounding structures or due to toxic effects 
of the blood or due to increasing intracranial pressure.   
 
Fig 6. CAUSES OF ISCHEMIC STROKE 
 PATHOPHYSIOLOGY OF ISCHEMIC STROKE: 
 Occlusion of a cerebral blood vessel causes reduction in the regional 
blood flow. 
 The magnitude of blood flow reduction would depend on the extent of 
collateral blood flow. The reversible ischemic region surrounding a core area of 
infarction is called the ischemic penumbra which can be imaged by a 
perfusion- diffusion imaging.  
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The pathways leading to cerebral infarction include, 
1)  Necrosis resulting from energy failure and cytoskeletal breakdown 
2) Apoptotic pathway- caused by lesser degrees of ischemia 
 Ischemia starves the neuron of glucose and oxygen and thereby the 
mitochondrial pathway of ATP formation is affected, leading to dysfunction of 
the membrane pumps and thereby persistent depolarisation, glutamate release. 
This increases calcium influx and membrane phospholipid damage releasing 
free radicals. Free radicals cause oxidant stress and induce apoptosis. 
 Additional stressors like fever, hyperglycemia and electrolyte 
disturbances can aggravate the ischemic process and worsens the degree of 
brain injury and rapid correction of the above is mandatory. 
 
Fig 7. PATHOPHYSIOLOGY OF ISCHEMIC STROKE 
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HEMORRHAGIC STROKE 
 10% of strokes are due to Intracerebral haemorrhage. Hypertension, 
coagulopathy drugs like cocaine and methamphetamine, and cerebral amyloid 
angiopathy are major causes of ICH. Hypertensive ICH occurs due to 
spontaneous rupture of penetrating arteries due to high blood pressure. CT 
imaging is the best investigation for identifying and locating ICH. 
 
 
 
 
Fig 8. CAUSES OF INTRACRANIAL HEMORRHAGE 
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VASCULAR TERRITORIES INVOLVED IN STROKE 
 The brain parenchyma is supplied by two major arterial territories with a 
good collaterals through the circle of Willis 
The major territories include:  
1) Anterior circulation – by the branches of the Internal Carotid Artery- 
mainly the anterior cerebral, middle cerebral and anterior choroidal 
arteries 
2)  Posterior circulation- comprised of Vertebral arteries, basilar artery and 
posterior cerebral arteries 
BLOOD SUPPLY TO BRAIN 
 
Fig 9.CORTICAL AREAS- LATERAL ASPECT 
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Fig 10. CORTICAL AREAS- CORONAL SECTION 
 
Fig 11. CORTICAL AREAS- MEDIAL ASPECT 
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Anterior circulation Stroke: 
The middle cerebral artery supplies  
1) The entire lateral cerebral surface except  
a) The frontal pole and a small strip in the superomedial region in frontal 
and   parietal    lobes– supplied by the ACA 
 b) lower temporal and occipital pole convolutions- supplied by the PCA 
2) putamen, outer globus pallidus, posterior limb of internal capsule, corona 
radiata and most of the caudate nucleus – all supplied by the penetrating 
branches from the proximal MCA 
The Anterior cerebral artery is divided into two segments 
1)  A1 segment gives penetrating branches supplying anterior limb of 
internal capsule, anterior perforated substance, amygdala, anterior 
hypothalamus, inferior part of head of caudate nucleus 
2)  A2 supplies the superomedial surface of the frontal lobe 
 
The Anterior Choroidal Artery –  
 Arises from the ICA and supplies the posterior limb of the internal 
capsule and the adjacent posterolateral white mater. 
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Posterior circulation Stroke 
Two patterns of posterior circulation involvement are seen: 
1)  P1 syndrome- midbrain, subthalamic and thalamic involvement due to 
occlusion of P1 segment of PCA or its penetrating branches 
2)  P2 syndrome- Cortical temporal and occipital lobe involvement due to 
involvement of the PCA distal to the posterior communicating artery (P2 
segment) 
IMAGING IN STROKE 
CT scan 
 CT serves to exclude or identify hemorrhagic stroke. Generally CTs 
obtained in the first few hours in ischemic stroke may show no abnormality, for 
upto 24 to 48 hours. 
 CT is not the best imaging modality in posterior circulation strokes due to 
bone artifacts and might miss small cortical surface infarcts. 
 Contrast enhanced CT can better visualise subacute infarcts, perfusion 
imaging can detect the ischemic penumbra. CT is sensitive for identifying 
SAH. CT angiography can identify intracranial aneurysms 
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Fig 12. CT IMAGING OF INTRACEREBRAL HEMORRHAGE 
MRI 
 MRI can reliably give the extent and the location of the infarct, including 
a good visualisation of the posterior fossa. Diffusion weighted imaging is very 
sensitive for acute cerebral infarction. MR perfusion studies with gadolinium 
contrast can accurately define the penumbra.  
Cerebral Angiography 
 Conventional X-ray cerebral angiography remains the gold standard for 
quantifying the atherosclerotic stenosis in the cerebral arteries. But this has the 
risk of arterial damage, embolic stroke and contrast nephropathy and is hence 
reserved for special situations 
Ultrasound 
 Doppler ultrasound can identify and quantify stenosis at the proximal 
internal carotid artery. Transcranial Doppler identifies thrombosis in the large 
intracranial vessels by measuring systolic flow velocity. An MR angiogram 
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combined with ultrasound techniques can eliminate the need for Conventional 
cerebral angiography. 
Perfusion techniques 
 Xenon CT and PET can quantify cerebral blood flow but are mainly used 
in research. 
 SPECT and MR perfusion techniques can give the relative blood flow. 
 MR perfusion combined with DW MRI can identify the ischemic 
penumbra. 
TREATMENT OF STROKE 
ISCHEMIC STROKE 
 The immediate goal in acute ischemic stroke is to give adequate perfusion 
to the ischemic penumbra. Within 6 hours of onset, iv thrombolysis is ideal and 
the preferred agent is rtPA. Endovascular revascularisation uses intra-arterial 
thrombolysis. Among the antiplatelets the only drug with proven efficacy is 
aspirin. 
 Anticoagulants have not shown significant benefit over risk.  
HEMORRHAGIC STROKE 
 Mortality in acute hypertensive ICH is 40% . the ICH score can stratify 
the mortality risk of the patients. Any underlying coagulopathy should be 
rapidly corrected. If patient is on VKA then prothrombin complex concentrates 
are used. Cerebellar hemorrhages >3cm diameter needs surgical evacuation. 
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Osmotic agents are administered in case of mass effect or hydrocephalus or 
coma. Glucocorticoids are not useful in intra-cerebral hematoma induced 
edema. Prevention of ICH needs blood pressure control in hypertensives, 
avoidance of excessive alcohol and illicit drugs.  
 
 
Fig 13. TREATMENT ALGORITHM FOR STROKE 
HYPONATREMIA IN STROKE 
In patients with stroke, hyponatremia can be a cause of persistent altered 
sensorium. Neurologic dysfunction in hyponatremia occurs due to cerebral 
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edema and due to cerebral autoregulation. The complications of hyponatremia 
are more marked with acute and severe Sodium reductions [40]. 
 If the fall in sodium levels occur within a span of three days, cerebral 
edema is marked. 
 The symptoms of nausea and malaise occur at sodium levels 125-
130mEq/L. Headache, obtundation, seizures, coma, respiratory failure and non-
cardiogenic pulmonary edema can occur at levels 115-120mEq/L. 
Hyponatremia by resulting in adverse situations like seizures and coma can 
cause further deterioration of the patient.  
 Hyponatremia in stroke is mostly hypo-osmolal and is due to either 
SIADH or CSW [41].   
 Precipitating factors include dietary sodium restriction, diuretics and 
infections. 
 In a study by Sheikh et al, the incidence of hyponatremia in stoke was 
found to be 35% out of which 67% had SIADH and 33% had CSW. 
Hyponatremia had significant impact on the outcome especially in patients with 
CSW [40].  
  In another study by Huang WY et al, hyponatremia in acute stroke was 
seen in 11.6%. Hyponatremia was also a predictor of three-year mortality in 
acute ischemic stroke patients [41]. 
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MATERIALS AND METHODS 
(i) SOURCE OF DATA : Data consists of primary data collected by the 
principal investigator directly from the patients who are admitted in 
the Government Medical College and Hospital 
(ii) STUDY AREA:  Coimbatore Medical College hospital  
(iii) DESIGN OF STUDY: Cross sectional study 
(iv) PERIOD OF STUDY: One year,  July 2014-  July 2015 
(v) SAMPLE SIZE: Based on past records and previous evidence, it is 
expected that about fifty number of cases would be available during 
the period of study. 
(vi) DEFINITION USED IN THE STUDY 
• STROKE  
"Neurological deficit of cerebrovascular cause that persists beyond 
24 hours” 
• HYPONATREMIA 
Hyponatremia is defined as sodium level < 130 meq/L 
True hyponatremia is defined as those patients with a sodium level of 
130 meq/L and plasma osmolality less 275 mosm/kg  
• PLASMA OSMOLALITY 
              The plasma osmolality is calculated using the formula-  
2(Na)+ Glu/18+ BUN/2.8 
              (Na- Plasma Sodium, Glu-Plasma glucose, BUN- Blood urea nitrogen) 
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•  SODIUM CORRECTION 
Total body water (TBW) - 50% of body weight in females 
                                             60% of body weight in males 
Free water deficit-[(Na+ - 140) / 140]* TBW 
Free water clearance- V * [1-    (UNa +UK) / P Na] 
V- Urinary volume; UNa - Urinary sodium, UK - Urinary potassium;  
PNa- Plasma Sodium 
NORMAL RANGES OF PARAMETERS USED IN THE STUDY 
Plasma Osmolality  - 275 – 295 mosm/kg 
Serum Potassium   -  3.5- 5 m Eq/L 
Serum Albumin      - 3.5- 5 g/dl  
Hematocrit            - Male: 40.7-50% 
Female: 36.1-44.3%  
               Serum Uric acid     - Male: 3.4-7 mg/dl  
     Female: 2.4-6 mg/dl  
BUN/ Creatinine  - 10:1-20:1 
INCLUSION CRITERIA: 
Confirmed cases of stroke by history, neurologic and imaging 
modalities. 
EXCLUSION CRITERIA:  
The following patients are excluded: 
• Head injury 
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• CNS tumor 
• Pulmonary tuberculosis 
• Bacterial pneumonia 
• Bronchogenic carcinoma 
• Hematologic malignancies 
• Recent surgery 
• Meningitis 
• Encephalitis 
• Drug usage- SSRI, TCA, narcotics, NSAIDs, Antipsychotics, 
Carbamazepine, Cyclophosphamide, clofibrate, chlorpropamide 
About 50 stroke patients admitted to Coimbatore Medical College 
Hospital during the one year study period (August 2014 to September 2015) 
were studied. 
The diagnosis was confirmed by imaging- CT scan or MRI.  
The stroke type- ischemic or hemorrhagic, the side of the stroke and the 
involved vascular territory was confirmed using the imaging study.  
After ruling out the exclusion criteria, serial serum sodium levels were 
done. In patients with hyponatremia, plasma osmolality was measured to 
differentiate between true and pseudo-hyponatremia. Cerebral causes of 
hyponatremia were identified and classified as SIADH/CSW and treated as per 
the standard protocol. The patient was put on in-patient follow-up till 
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discharge/ death. The patients with prior/ admission diuretic usage are not 
taken into the study group as cases.   
Day1  
Clinical estimation of Extracellular fluid volume – estimated by  
Jugular venous pressure elevation,  
Peripheral edema,  
Negative/ positive fluid balance by input /output,  
Blood pressure levels    
On Day 1 of hyponatremia, levels of 
Serum Sodium 
Plasma osmolality  
Serum potassium  
Serum uric acid  
Hematocrit  
BUN/ Creatinine ratio 
Serum albumin 
Urine Sodium are measured.  
This helps in tentative differentiation between SIADH and CSW. 
 Based on Day 1 values,  
 
Sodium correction is carried out using the standard protocols i.e., fluid 
restriction in case of SIADH and intravenous saline in case of suspected CSW; 
hypertonic saline where severe hyponatremia is encountered.  
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 Serial Day 5 values  
 Serum sodium,  
 Serum uric acid,  
Hematocrit,  
 Serum albumin  
were measured and confirmatory assessment of SIADH / CSW was made.  
A short term follow up of the outcome of the patient till discharge/ death 
was done to see whether hyponatremia could affect the outcome of the patient 
significantly.   
INVESTIGATIONS 
• Chest X-ray 
• CT scan brain/ MRI brain 
• Plasma osmolality 
• Urine sodium 
• Plasma sodium 
• Serum Potassium 
• Hematocrit 
• Serum Uric acid 
• Serum Albumin 
• BUN / Creatinine ratio 
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DIAGNOSTIC APPROACH 
Stroke 
(confirmed by imaging) 
 
Plasma Sodium low 
Plasma Osmolality low 
 
True Hyponatremia 
 
Assess 
• Clinical volume status 
• Urine Sodium 
• Serum Uric acid  
• BUN/ creatinine ratio 
• Serum Potassium 
• Hematocrit 
• Serum Albumin 
 
 
          SIADH                                           CSW 
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STATISTICAL ANALYSIS 
The data are reported as the mean +/- SD or the median, depending on 
their distribution. 
The differences in quantitative variables between groups were assessed 
by the unpaired t test. 
Comparison between groups was made by the Non parameteric Mann - 
whitney test 
ANOVA was used to assess the quantative variables. 
A Chi Square test was used to assess differences in categoric variables 
between groups.  
Kaplan Meiyer was performed       
A p value of <0.05 using a two-tailed test was taken as being of 
significance for all statistical tests.  
All data were analysed with the statistical software package. (SPSS, 
version 16.0 for windows)       
 
 
 
 
 
 
 

 STROKE ANALYSIS 
 
TABLE 
  
AGE 
21 -40 
41 – 60 
61 – 80 
>80 
TOTAL 
CHART 1. COMPARISION OF AGE DISTRIBUTION WITH GENDER
 
 
 
 
 
 
 
21 -40
41 - 60
61 - 80
>80
0%
5%
10%
15%
20%
25%
30%
35%
40%
45%
Age Distribution with Gender 
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RESULTS 
 
 
1. AGE DISTRIBUTION 
GENDER     
MALE FEMALE TOTAL (%)
4 1 5 10%
20 3 23 46%
12 5 17 34%
2 3 5 10%
38 12 50 
 
 
MALE FEMALE
8% 2%
40% 6%
24% 10%
4% 6%
[N=50][p>0.05]
 
 
 
 
 
  
 
 In our set of stroke patients, the majority of the patients, around 46% 
(n= 23) belonged to the middle aged group 
patients belonged to the extreme age groups
The majority of males belonged to 40
prevalence of stroke in females was most seen to be in the 60 to 80 year age 
group (n=5) 
CHART 2
Of the 50 stroke patients 76% (n= 38) are male and 24% (n= 12) were female
 
44 
(40 – 60 years of age), 10% of 
, <40 years and >80 years.
-60 years age group, (n=20). The 
. SEX DISTRIBUTION 
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TABLE 2. MEAN AGE WITH GENDER COMPARISION 
Mean Age with Gender   
  
Mean 
SD 
95% CI for 
Mean 
Minimum Maximum Sig Gender [Years] Lower Upper 
MALE 56.2 14.5 51.4 61.0 27 95   
FEMALE 66.9 17.3 55.9 77.9 26 88 <0.05 
Total 58.8 15.8 54.3 63.2 26 95   
 
CHART 3. BOX PLOT OF AGE vs GENDER 
 
 
 
 
 
 
 
In our study group patients, we found 
The mean age of males with stroke to be 56.2 (± 14.5)  
The mean age of the females with stroke to be 66.9 (± 17.3) 
  
 STROKE TYPE
Ischemic 
Intracerebral 
Hemorrhage
Subarachnoid 
Hemorrhage
Total 
In our study, the majority of the patients had ischemic stroke around 
80% (n=40), of which 6 patients had lacunar stroke, 5 patients had a massive 
infarct. Hemorrhagic stroke was seen in 10 patients, with 8 patients (16%) 
having intracerebral bleed
haemorrhage was accelerated hypertension.
had aneurysmal bleed presenting sub
Intracerebral 
hemorrhage
(16%)
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TABLE 3. STROKE TYPE 
 n (%) 
40 80%
 
8 16%
 
2 4% 
50 100%
 
CHART 4. STROKE TYPE 
.  In 4 patients with intra cerebral bleed, the cause of 
 2 patients with hemorrhagic stroke 
-arachnoid haemorrhage (4%)
Ischemic
80%
SAH 4%
Stroke Type [N=50]
 
 
 
 
 
 TABLE 
TERRITORY
 ACA 
MCA 
PCA 
Total 
 
CHART 
The majority of patients in our study i.e., 26 patients (52%), had stroke 
corresponding to the Middle Cerebral Artery territory, followed by 20 patients 
(40%) with Posterior cerebral artery 
Anterior Cerebral circulation involvement.
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4. STROKE TERRITORY 
 n (%) 
4 8% 
26 52% 
20 40% 
50 100% 
5. STROKE TERRITORY 
involvement and 4 patients (8%) with 
 
 
ACA
8%
MCA
52%
PCA
40%
Territory [N=50]
 
 TABLE 5. SIDE OF THE CEREBRAL INVOLVEMENT
SIDE 
Right 
Left 
Bilateral
Total 
 
CHART 6
In our study, most of the patients had Right sided stroke 54% (n=27), 
28% had left sided stroke (n=14) and 18% (n=9) had bilateral involvement. 
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N (%) 
27 54% 
14 28% 
 9 18% 
50 100% 
. SIDE OF CEREBRAL INVOLVEMENT
 
Right
54%
Left
28%
Bilateral
18%
SIDE [N=50]
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TABLE 6: ASSOCIATION OF DEMOGRAPHIC VARIABLES & 
CLINICAL VARIABLES WITH HYPONATREMIA 
 
 
Clinical HYPONATREMIA   
Variables Without 
[n=37] 
SIADH 
[n=6] 
CSW 
[n=4] 
Others[
n=3] Sig 
AGE 
          
21 -40 5 0 0 0   
% 14% 0% 0% 0% 
  
41 – 60 21 2 0 0   
% 57% 33% 0% 0% <0.05 
61 – 80 7 4 3 3   
% 19% 67% 75% 100%   
>80 4 0 1 0   
% 11% 0% 25% 0%   
GENDER 
        
Male 30 4 3 1   
% 81% 67% 75% 33%   
Female 7 2 1 2   
% 19% 33% 25% 67% >0.05 
Types of Stroke 
        
Ischemic 30 5 2 3   
% 
81.10% 83.30% 50.00% 
100.00
% 
  
Hemorrhagic 7 1 0 0   
% 18.90% 16.70% 0.00% 0.00% <0.001 
Ischemic+Hemorrhagic 0 0 2 0   
% 0.00% 0.00% 50.00% 0.00%   
TERRITORY 
        
ACA 4 0 0 0   
% 10.80% 0.00% 0.00% 0.00% 
  
MCA 20 2 3 3   
% 
54.10% 33.30% 75.00% 
100.00
% >0.05 
PCA 13 4 1 0   
% 35.10% 66.70% 25.00% 0.00%   
SIDE 
          
RIGHT 20 4 3 0   
% 54.10% 66.70% 75.00% 0.00% 
  
LEFT 12 1 0 1   
% 32.40% 16.70% 0.00% 33.30% >0.05 
BILATERAL 5 1 1 2   
% 13.50% 16.70% 25.00% 66.70%   
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TABLE 7.ASSOCIATION OF BIO CHEMICAL PROPERTIES WITH 
HYPONATREMIA 
BIO CHEMICAL PROPERTIES       
Clininal HYPONATREMIA   
Variables 
  SIADH [n=6] CSW [n=4] 
Others[
n=3] Sig 
Volume Status 
        
Increased   3 0 0   
%   50.00% 0.00% 0.00%   
Decreased 0 4 0   
%   0.00% 100.00% 0.00% <0.05 
Normal   3 0 0   
%   50.00% 0.00% 0.00%   
Uric Acid -day5 
        
Decreased 0 3 0   
%   0.00% 75.00% 0.00% <0.05 
Normal   5 0 0   
%   100.00% 0.00% 0.00%   
1BUN/ Creatinine  
      
Increased   0 4 1   
%   0.00% 100.00% 33.30%   
Decreased 5 0 0   
%   100.00% 0.00% 0.00% <0.05 
Normal   0 0 1   
%   0.00% 0.00% 33.30%   
HCT Day5 
        
Increased   0 2 0   
%   0.00% 50.00% 0.00%   
Decreased 2 0 0   
%   33.30% 0.00% 0.00% <0.05 
Normal   4 1 0   
%   66.70% 25.00% 0.00%   
Albumin Day 5 
        
Decreased 1 0 0   
%   16.70% 0.00% 0.00% <0.05 
Normal   5 3 0   
% 
  83.30% 75.00% 0.00%   
Urine Sodium 
        
Increased   6 4 1   
%   100.00% 100.00% 33.33%   
Decreased 0 0 2   
%   0.00% 0.00% 66.67% <0.05 
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TABLE. 8 CLINICAL VARIABLES MEAN 
 
TABLE 9.  MEAN DAY OF HYPONATREMIA DEVELOPMENT 
  
Mean 
SD 
95% CI for 
Mean 
Minimum Maximum Sig Hyponatremia [Days] Lower Upper 
SIADH 3.3 3.2 0.0 6.7 1 9   
CSW 3.0 1.8 0.1 5.9 1 5   
Others 3.3 1.5 -0.5 7.1 2 5 >0.05 
Total 3.2 2.4 1.8 4.7 1 9   
 
 
 
 
  
    
Mean SD 
95% CI for Mean 
Minim
um 
Ma
xi
mu
m 
Maxim
um 
  Hyponatremi
a 
Lower Upper 
Na Day 1 With  127.08 3.252 125.11 129.04 117 130   
without 139.03 4.2 137.63 140.43 130 148 <0.001 
Total 135.92 6.602 134.04 137.8 117 148   
Plasma 
Osmo 
With  
270.52 16.17 260.75 280.30 248 299   
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CHART 7. MEAN DAY OF HYPONATREMIA DEVELOPMENT 
 
The mean day of development of hyponatremia was 3.2 days and there 
was no significant difference in the day of development of hyponatremia 
between the various groups. (p>0.05) 
  
 TABLE 10. 
  
Hyponatremia
Without Hyponatremia
Total 
 
CHART 8
The prevalence
20% of the 50 studied stroke patients (n=10) 
 
Hyponatremia
Prevalence of Hyponatremia [N=50]
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PREVALENCE OF HYPONATREMIA
n (%)
 10 20%
 40 80%
50 100%
. PREVALENCE OF HYPOATREMIA
 of hyponatremia due to cerebral causes was noted in 
 
 
Hyponatremia
20%
Without 
80%
 
 
 
 
 
 
 
 TABLE 11. PREVALENCE
  
SIADH 
CSW 
Others 
Total 
 
CHART 
 
PREVALENCE OF HYPONATREMIA 
54 
 OF SIADH AND CSW
n (%) 
6 12% 
4 8% 
3 6% 
13 26% 
9. PREVALENCE OF SIADH AND CSW
 
SIADH
46%
CSW
31%
Others
23%
[n=13]
 
 
 
 CHART 10. HYPONATREMIA PREVALENCE IN STROKE
Of the 50 patients, 12% had SIADH (n=6) and 8% had CSW 
(n=4),Other causes of hyponatremia
attributed to diarrhoea (n=1), renal failure (n=1) and congestive cardiac failure 
(n=1). 
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In general, the occurrence of hyponatremia due to cerebral causes was 
noted most in the 61-
hyponatremia was 20% in 41
group.The difference in the hyponatremia prevalence among the various age 
groups reached statistical significance (p<0.05)
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1. AGE DISTRIBUTION IN STROKE
80 year age group i.e., 70% (n=10). The occurrence of 
-60 year age group and 10% in the > 80 year age 
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 TABLE 13. AGE DISTRIBUTION OF SIADH AND CSW
  
Age SIADH
41 - 60 
61 - 80 
>80 
Total 
 
CHART 12. AGE DISTRIBUTION OF SIADH AND CSW
All the patients who developed SIADH were of the age group of 41
years, with about 67% (n=4) coming under the 61
occurrence of SIADH was 33% in the 41
who developed Cerebral Salt Wasting on the
group of 61 years and above, with the majority belonging to the 61
group, 75% (n=3). The occurrence of CSW in the age group >80 years was 
25% 
SIADH[n==6]
41 - 60 33%
61 - 80 67%
>80 0%
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CHART 13. GENDER DISTRIBUTION
Of the patients with hyp
were males and 30% 
in the incidence of hyponatremia based on the gender (p>0.05)
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 IN HYPONATREMIA
onatremia due to cerebral cause
(n=3) were females. There was no significant difference 
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 TABLE 15. GENDER DISTRIBUTION OF SIADH AND CSW
 
 
 
 
CHART 14. GENDER DISTRIBUTION OF SIADH AND CSW
In the SIADH group, the majority of patients were males 67% (n=4) and 
females comprised of 33% (n=2).
majority of the patients was male 75% (n=3), whereas females 
25% (n=1). The variation in sex distribution among the various groups did not 
reach statistical significance.(p > 0.05)
causes of hyponatremia, the majority were females, 67%.
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 In the CSW group also the gender of 
comprised about 
. In the group of patients who had other 
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 TABLE 16. 
  
STROKE 
TYPE 
Ischemic 
Intracerebral 
hemorrhage 
SAH 
TOTAL 
CHART 15
All the subarachnoid haemorrhage patients in our study developed 
hyponatremia(n=2).Out of the Ischemic stroke patients 18% had hyponatremia. 
(n=7). Hyponatremia was seen in 13% of patients with intracerebral 
haemorrhage. 
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Without Hyponatremia 
Assoication of Hyponatremia subjects with Stroke 
60 
STROKE TYPE IN HYPONATREMIA
HYPONATREMIA     
WITH WITHOUT TOTAL 
7 33 40 
1 7 8 
2 0 2 
10 40 50 
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Ischemic[n=40] Hemorrhagic[n=8] SAH (n=2)
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 TABLE 17.
  
Stroke Type 
Ischemic 
Hemorrhagic 
SAH 
Total 
CHART 16
Among patients with hyponatremia, 77% had 
8% had intra-cerebral haemorrhage (n=1), and 23% (n=2)
haemorrhage. Among SIADH patients, 73% had ischemic stroke and 18% had 
intra cerebral hemorrhage. Among cerebral salt wasting patients, ischemic 
stroke was found in 50% of patients and
difference in stroke type seen in the various conditions did not however, reach 
statistical significance.
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Hyponatremia 
SIADH CSW Others TOTAL
5 2 3 10 
1 0 0 1 
0 2 0 2 
6 4 3 13 
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CHART 17. STROKE TERRITORY
 
50% of the hyponatremia patients had
involvement and 50% had Middle cerebral Artery territory involvement. 
of our patients with ACA territory stroke developed hyponatremia
 
 
 
With Hyponatremia [n=10]
Without Hyponatremia 
[n=40]
Assoication of Hyponatremia subjects with Territory 
62 
 IN HYPONATREMIA
HYPONATREMIA     
WITH WITHOUT TOTAL 
0 4 4 
5 23 28 56%
5 13 18 36%
10 40 50 
 IN HYPONATREMIA
 Posterior Cerebral Artery territory 
ACA MCA
0% 50%
10% 58%
0%
10%
20%
30%
40%
50%
60%
70%
[n=50][p>0.05]
 
(%) 
8% 
 
 
  
 
 
  None 
. 
PCA
50%
33%
 TABLE 19. TERRITORY IN SIADH AND CSW
  
Territory 
MCA 
PCA 
Total 
CHART 1
The majority of patients with SIADH had a posterior circulation stroke, 
67% (n= 4), and 33% (n=2 had Middle Cerebral Territory stroke.
In CSW, 75% (n=3) had Middle Cerebral Artery territory involvement 
and  25% had posterior circulation stroke.
hyponatremia, the territory involved 
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 In the group with other causes of 
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CHART 19. 
Of the patients with cerebral cause of hyponatremia
sided involvement, 20% had bilateral and 10% had left sided involvement.
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1 13 14 
2 7 9 
10 40 50 
 SIDE OF CEREBRAL INVOLVEMENT
, 70% had a right 
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TABLE 21. SIDE vs SIADH AND CSW 
  Hyponatremia   
SIDE SIADH CSW Others TOTAL (%) 
Right 4 3 0 7 54% 
Left 1 0 1 2 15% 
Bilateral 1 1 2 4 23% 
Total 6 4 3 13   
 
4 patients with SIADH and 3 patients with CSW had right sided 
involvement. Left sided involvement was seen in 1 patient with SIADH. 2 
patients (1- SIADH and 1- CSW) had bilateral arterial involvement. 
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TABLE 22. DURATION OF HOSPITAL STAY 
  
Mean 
SD 
95% CI for 
Mean 
Minimum Maximum Sig Hyponatremia [Days] Lower Upper 
WITH 17 34.247 -3.7 37.7 1 130   
WITHOUT 3.73 1.866 3.11 4.35 1 10 <0.05 
Total 7.18 18.01 2.06 12.3 1 130   
 
The mean duration of hospital stay was significantly different in patients 
with hyponatremia 17 days as against 3.73 days in normonatremic patients 
The maximum duration of stay seen in one of the hyponatremic patients 
was 130 days.  
 
CHART 20. DURATION OF HOSPITAL STAY 
 
67 
 
TABLE 23. SURVIVAL TIME 
Kaplan-Meier 
Means and Medians for Survival Time 
Meana Median 
Estimate Std. Error 
95% Confidence 
Interval 
Estimate 
Std. 
Error 
95% 
Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Upper 
Bound 
92.411 13.566 65.823 119 130 0 . . 
a. Estimation is limited to the largest survival time if it is censored. 
 
 
CHART 21. SURVIVAL TIME 
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TABLE 24. SURVIVAL TIME vs AGE 
Means and Medians for Survival Time vs Age 
Meana Median 
Estimate Std. Error 
95% Confidence 
Interval 
Estimate 
Std. 
Error 
95% 
Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Upper 
Bound 
80.899 3.106 74.812 86.986 81 4.865 71.464 90.536 
   
a. Estimation is limited to the largest survival time if it is censored. 
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 TABLE 25
  
Outcome 
Cure 
Death 
TOTAL 
Among the stroke patients, 80% were cured and 20% succumbed to the 
illness. 
CHART 23
 
In normonatremic stroke patients, an 85% cure rate and 15% death rate 
was seen. In hyponatremic
cure and death rate between the two groups reached a statistical significance. 
(p<0.05) 
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 TABLE 26. TREATMENT 
  
Out 
Come 
Without 
[n=37] 
Cure 32 
Death 5 
Total 37 
 
CHART 24. TREATMENT OUTCOME IN SIADH vs CSW
 
In the SIADH group, 83% were cured of hyponatremia
and 17% patients succumbed. But in the CSW group, only 25% survived and 
75% succumbed to the illness. The difference in outcome between the two 
groups reached statistical significance (p< 0.05)
 
Without [n=37]
Cure 86%
Death 14%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Treatment Outcome with Hyponatremia [n=13][p<0.05]
70 
OUTCOME OF SIADH vs CSW
HYPONATREMIA 
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CHART 25. BOX PLOT OF TREATMENT OUTCOME 
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DISCUSSION 
STROKE 
In our study we analysed 50 patients with acute stroke to study the 
occurrence of hyponatremia. 
  The majority of stroke patients, about 46%, belonged to the middle age 
i.e., 40 – 60 years of age. 
 The mean age of stroke occurrence in males was 56.2 (± 14.5) and that of 
the females was 66.9 (± 17.3). 
This is comparable to the population based study by Dalal et al (42) in 
Mumbai where the mean age for stroke was 66 years, and in Trivandrum by 
Sridharan et al (43) where the mean age was 67 years. 
The majority of males belonged to 40-60 years age group. The 
prevalence of stroke in females, however was higher in the 60 to 80 year age 
group. Thus a higher age stratified prevalence for females was found, which is 
comparable to the data from the 2008 Mumbai stroke registry (42) where a 
mean of 63.4 years was recorded for females. 
Of the stroke patients in our study group, 76% were male and 24% were 
female 
The prevalence of ischemic stroke was higher (80%), of which 6 
patients had lacunar stroke, 5 patients had a massive infarct. 
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Hemorrhagic stroke was seen in 20%, with 16% having intracerebral 
bleed and 4% having sub-arachnoid haemorrhage.  
This is comparable to the Mumbai stroke registry (42), where 80% of 
strokes were attributed to be ischemia and 17.7% to haemorrhage.  
Accelerated hypertension was the cause of haemorrhage in 4 patients 
with intra cerebral bleed. 
 52% had stroke corresponding to the Middle Cerebral Artery territory, 
40% with Posterior cerebral artery involvement and 8% with Anterior Cerebral 
circulation involvement. 
HYPONATREMIA 
The prevalence of hyponatremia due to cerebral causes was noted in 
20% of the acute stroke patients. The prevalence is slightly higher than the 
study by Kuramatsu et al (44) where prevalence was 15%. Rodrigues B (43) 
reported a prevalence of 16% and Soiza et al (45) 13.8%. 
Of the hyponatremic patients, there was a higher prevalence of SIADH 
(46%). CSW contributed to 31%. The study by Saleem et al (15) showed the 
respective prevalences to be 67% and 33%  
The prevalence of hyponatremia was the most in the 61-80 year age 
group (70%). 
The prevalence was lower among other age groups and this reached 
statistical significance (p<0.05). 
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67% of the patients who developed SIADH were of the 61-80 years age 
group. 
All the patients who developed Cerebral Salt Wasting on the other hand 
belonged to a higher age group (> 65 years). (p<0.05) 
The trend of hyponatremia prevalence was more in males (70%) but did 
not reach statistical significance (p>0.05) 
Both SIADH and CSW showed a higher male prevalence, 67% and 75% 
respectively. 
All the subarachnoid haemorrhage patients in our study developed 
hyponatremia 
Out of the Ischemic stroke patients 18% had hyponatremia.  
Hyponatremia was seen in 13% of patients with intracerebral 
haemorrhage. The most common stroke type seen in hyponatremic patients was 
ischemic stroke (77%) 
Among SIADH patients, 83% had ischemic stroke and 17% had intra 
cerebral hemorrhage. Saleem et al (15) in his study, showed 35% and 65% 
respectively. 
 Among cerebral salt wasting patients, ischemic stroke was found in 
50% of patients and SAH was found in 50% patients. In the study by Saleem et 
al 33% and 67% were the prevalence. (15) 
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Of the hyponatremia patients, 50% of patients had Middle cerebral 
territory and 50% had posterior cerebral artery territory involvement. 
None of our patients with ACA territory stroke developed hyponatremia. 
The majority of patients with SIADH had a posterior circulation stroke, 
67%, and 33% had Middle Cerebral Territory stroke. 
Saleem et al (15) however, reported 13% and 86% respectively 
In CSW, 75% had Middle Cerebral Artery territory involvement and 
25% had posterior circulation stroke. 
This was comparable with Saleem et al’s study (15%) who reported 85% 
and 15% respectively. 
The mean duration of hospital stay was significantly different in patients 
with hyponatremia 17 days as against 3.73 days in normonatremic patients 
The maximum duration of stay seen in one of the hyponatremic patients 
was 130 days. 
A poorer discharge disposition was seen in the hyponatremia group in 
the study by Rodrigues(43) 
In normonatremic stroke patients, an 85% cure rate and 15% death rate 
was seen.  
In hyponatremic patients, there was 60% cure and 40% death. This is 
similar to the death rate reported by Saleem et al, 40%. (15) 
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In both the studies, the presence of hyponatremia was found to 
significantly alter the treatment outcome in patients with stroke (p<0.05) 
Kuramatsu et al showed that in-hospital mortality was roughly doubled 
in hyponatremia compared with nonhyponatremia patients (40.9% vs 21.1%), 
translating into a 2.5-fold increased odds ratio (P<0.001). Also, Multivariable 
analyses identified hyponatremia as an independent predictor of in-hospital 
mortality (P=0.037) (44 
In the SIADH group, 83% were cured of hyponatremia with treatment 
and 17% patients succumbed. But in the CSW group, only 25% survived and 
75% succumbed to the illness. CSW was significantly associated with higher 
death rate. (p<0.05) 
Survival Curves 
The Kaplan Meier analysis showed a significant increase in duration of 
hospital stay poorer survival in patients with hyponatremia.  
Huang W.-Y proved that hyponatremia in the acute stroke stage was 
associated with higher mortality in hospital (P = .039) and at 3-month (P = 
.001) and 12-month follow-ups (P = .001), and that it is an independent 
predictor of 3-year mortality in patients with acute first-ever ischemic 
stroke.(46) 
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CONCLUSION 
 Hyponatremia in the setting of acute stroke occurs in 10-20% patients. 
 The prevalence is higher in males and among the middle aged. 
 Hyponatremia, attributed to CSW is more common in stroke patients 
with sub-arachnoid haemorrhage.  
 Hyponatremia occurs more with Middle and Posterior cerebral arterial 
territories involvement.   
 SIADH has a higher prevalence than Cerebral Salt Wasting. 
 Hyponatremia and especially, cerebral salt wasting predisposes to a 
longer duration of hospital stay and poorer discharge disposition.  
 Hyponatremia, is an independent predictor of short and long term 
mortality in stroke.  
 Cerebral Salt wasting has a poorer short term outcome than SIADH.  
 Thus, a clear distinction between the two entities ought to be made 
and the appropriate treatment be carried out, to reduce the morbidity, 
short and long term mortality in acute stroke patients with 
hyponatremia. 
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SUMMARY 
This study is a cross-sectional study carried out to emphasise the 
importance of hyponatremia in the setting of a stroke and the impact it can 
have on the prognosis of the patient. This study was carried out in the 
premises of Coimbatore Medical College Hospital during a one year period. 
50 cases of strokewere selected in random basis and were followed up for 
occurrence of hyponatremia. 
 The prevalence of hyponatremia was found to be 20%. The causes of 
hyponatremia especially Cerebral Salt Wasting and SIADH were studied. 
 It was found that hyponatremia per se, and Cerebral Salt Wasting in 
stroke resulted in poorer discharge disposition and longer duration of in-
hospital stay and significantly impacted on the short term in-hospital 
mortality. 
 The pathophysiology of the two conditions (SIADH and CSW) being 
entirely different need a completely differing treatment regime and hence the 
distinction between the two is of utmost importance in neurologic cases with 
hyponatremia
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PROFORMA 
DEPARTMENT OF MEDICINE, CMC 
NAME :  
AGE :  
SEX :  
IP NUMBER :  
ADDRESS :  
PHONE NUMBER :  
Date of admission 
Date of Discharge/ Death 
Duration of Hospital stay 
PRESENTING COMPLAINTS:  
o Weakness  
o Seizures   
o Giddiness  
o Unresponsiveness  
o Unsteadiness of gait  
o Deviation of angle of mouth  
 
viii 
 
DURATION OF SYMPTOMS :  
H/o FEVER/ TRAUMA  
PAST HISTORY :  
o Prior stroke  
o Diabetes mellitus  
o Hypertension  
o Cardiac disease  
o Epilepsy  
o Tuberculosis   
TREATMENT HISTORY:  
FAMILY HISTORY:  
ADDICTIONS :  
VITALS : Pulse- Rate & Rhythm  
                 Blood Pressure  
                 Respiratory Rate  
                 Temperature  
                 Daily input and output 
  
 
 
ix 
 
GENERAL EXAMINATION :  
SYSTEMIC EXAMINATION  
CENTRAL NERVOUS SYSTEM  
Higher Mental Functions: Consciousness   
                                            Orientation  
                                            Speech  
Cranial Nerves  
Motor system: Tone  
                          Power  
                          Reflexes   
Sensory system  
Cerebellar signs  
Meningeal signs  
GLASGOW COMA SCALE : E  V  M     Total score :    /15   
  
CARDIOVASCULAR SYSTEM  
Apex Beat  
Heart sounds   
Murmurs  
JVP 
x 
 
RESPIRATORY SYSTEM :  
Breath sounds  
Added sounds  
Percussion 
Vocal Resonance 
GASTROINTESTINAL 
SYSTEM  
Any tenderness  
Liver span   
Shifting dullness  
     General Parameters  
o Complete hemogram  
o Peripheral Smear 
o Random Blood Sugar  
o Blood urea  
o Serum creatinine 
o ECG : 
o Chest X-Ray 
o SPECIFIC PARAMETERS  
o CT scan Brain/ MRI Brain : 
xi 
 
o Day of development of Hyponatremia : 
o Day 1 of hyponatremia : 
Serum sodium : 
Plasma Osmolality : 
Urine Sodium 
Serum Potassium 
Serum uric acid :  
Serum albumin : 
BUN/ Creatinine 
Hematocrit 
Day 5 of Hyponatremia (safter attempted correction) : 
Serum uric acid 
Serum albumin 
Hematocrit 
Serum potassium 
OUTCOME OF THE PATIENT: Death / Recovery and discharge 
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CONSENT FORM 
 
You, Shri./ Smt./ Kum. _________________________, aged ____ years, S/o / 
D/o / W/o ___________________________, residing at ________________ 
_______________________________________ are requested to be a 
participant in the research study titled “Hyponatremia in stroke: Cerebral Salt 
Wasting versus Syndrome of Inappropriate Anti diuretic hormone 
secretion”conducted by Dr. Mithra Prasad., one of the post graduate trainees in 
the Dept. of General Medicine, Govt. Coimbatore Medical College and 
Hospital, Coimbatore. You are eligible for the study as per the inclusion 
criteria. You can ask her any question or seek from her any clarifications about 
the study which you may have before agreeing to participate in the study. 
TOPIC OF THE RESEARCH 
“Hyponatremia in stroke: Cerebral Salt Wasting versus Syndrome of 
Inappropriate Anti-Diuretic Hormone secretion” 
PURPOSE OF RESEARCH 
Hyponatremia is one of the most common abnormalities in patients with stroke 
and is also one of the most easily missed or mistreated electrolyte abnormality. 
Hyponatremia can significantly influence the outcome of stroke and thus 
warrants a proper correction. Both SIADH and cerebral salt wasting should be 
differentiated since treatment modalities differ. 
 
xiii 
 
PROCEDURES INVOLVED IN THE STUDY 
Properly elicited medical history pertaining to the patient’s complaints. 
Detailed general and systemic examination as guided by the medical history.  
Blood and imaging investigations as guided by the clinical diagnosis. 
Treatment with standard protocol currently followed in our hospital. 
Continued follow-up of patient in the intensive medical care unit and the ward 
Recording all the above variants/events into the database and analyzing them 
by statistical methods to arrive at our objectives. 
DECLINING FROM PARTICIPATION 
You are hereby made aware that participation in this study is purely voluntary 
and honorary, and that you have all the rights to decline from participating in it. 
PRIVACY AND CONFIDENTIALITY 
You are hereby assured that your privacy is respected. Any information about 
you or provided by you during the study will be kept strictly confidential. 
AUTHORIZATION TO PUBLISH RESULTS   
Results of the study may be published for scientific purposes and/or presented 
to scientific groups. In any case, neither will your identity be revealed nor will 
your privacy be breached. 
 
xiv 
 
STATEMENT OF CONSENT 
I, _____________________, do hereby volunteer and consent to participate in 
this study being conducted by Dr. Mithra Prasad I have read and understood the 
consent form (or) it has been read and explained to me thoroughly. I am fully 
aware of the study details as well as aware that I may ask questions to him at 
any time. 
 
 
Signature / Left Thumb Impression of the patient  
Station: Coimbatore 
Date: 
 
 
 
Signature / Left Thumb Impression and Name of the witness   
   
Station: Coimbatore 
Date: 
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xg;g[jy; gotk;; [ ; ;; [ ; ;; [ ; ; 
 
bgah;   : 
taJ   : 
ghypdk;  : 
Kfthp  : 
 
 muR nfhit kUj;Jtf; fy;Y}hpapy; bghJ kUj;Jt Jiwapy;  gl;;l nkw;gog;g[ 
gapYk; khztp kU. kpj;uh gpurhj;; ;; ;; ; mth;fs; nkw;bfhs;Sk; “gf;fthjj;jpy; cg;g[ rj;J ; ; ; ; [ ;; ; ; ; [ ;; ; ; ; [ ;
(nrhoak;) FiwghL ;;; : njitf;F mjpfkhd mst[ ; [; [; [ ADH Qhh;nkhd; Ruj;jy; fhuzj;jhyh ; ; ; ; ;; ; ; ; ;; ; ; ; ;
my;yJ ;;; \isapy; cg;g[ rj;J nja;khdj;jpdh; ; [ ; ; ;; ; [ ; ; ;; ; [ ; ; ; yh? ” gw;wpa Ma;tpy; bra;Kiw kw;Wk; 
midj;J tpsf;f';fisa[k; nfl;Lf; bfhz;L vdJ re;njf';fis bjspt[g;gLj;jpf; 
bfhz;nld; vd;gij bjhptpj;Jf; bfhs;fpnwd;. 
 ehd; ,e;j Ma;tpy; KG rk;kjj;JlDk;/ Ra rpe;jida[lDk; fye;J bfhs;s 
rk;kjpf;fpnwd;. 
,e;j Ma;tpy; vd;idg; gw;wpa midj;J tptu';fs; ghJfhf;fg;gLtJld; ,jd; 
Kot[fs; Ma;tpjHpy; btspaplg;gLtjpy; Ml;nrgid ,y;iy vd;gij bjhptpj;Jf; 
bfhs;fpnwd;. ve;j neuj;jpYk; ,e;j Ma;tpy; ,Ue;J ehd; tpyfpf; bfhs;s vdf;F chpik 
cz;L vd;gija[k; mwpntd;. 
,lk; : 
njjp :        ifbahg;gk; / nuif 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MASTER CHART 
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S.No IP NO. Age Sex Stroke type Territory Side Serum Sodium
Duration of 
hospital stay Outcome
1 48839 39 1 1 2 2 138 3 1
2 50299 55 1 1 2 1 136 2 1
3 53341 44 1 1 3 1 134 4 1
4 52039 38 1 1 2 2 141 5 1
5 52118 26 2 1 2 1 142 4 1
6 52725 27 1 1 1 2 135 4 1
7 55800 53 1 1 2 2 138 2 1
8 55365 52 1 1 3 2 136 3 1
9 57513 42 1 1 2 1 145 4 1
10 59062 37 1 1 2 1 143 5 1
11 59105 53 1 2 2 1 139 4 1
12 59060 43 1 1 3 2 138 10 1
13 56628 68 1 1 3 1 146 8 1
14 59238 41 1 1 2 2 143 3 1
15 60730 70 1 1 3 2 148 5 1
16 60877 48 1 2 3 1 135 3 2
17 61758 60 1 1 3 3 141 8 1
18 61144 48 1 2 2 2 141 3 1
19 57889 65 1 1 3 1 140 4 1
20 52269 88 2 2 3 3 141 2 2
21 55535 50 1 1 2 1 135 3 1
22 51122 61 1 1 3 2 136 3 1
23 54356 56 1 1 3 1 136 4 1
24 53741 70 2 1 2 1 131 4 2
25 60778 42 1 2 3 3 141 3 2
26 60999 56 1 1 2 1 138 2 1
27 55941 81 2 1 2 1 136 5 1
28 59108 59 2 1 2 1 138 1 1
29 53456 60 1 1 2 1 146 5 1
30 60998 70 1 1 2 2 142 4 1
31 59244 61 2 1 1 3 130 2 2
32 53334 58 1 1 3 1 141 2 1
33 55567 44 1 1 1 2 140 4 1
34 60456 49 1 2 2 1 138 2 1
35 50334 95 1 1 2 1 132 3 1
36 60948 57 2 1 1 3 144 1 1
37 60105 88 1 2 2 1 140 4 1
NORMONATREMIC GROUP (n=37) 
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S.No IP NO. Age Sex
Stroke 
type
Territory Side Na Day 1 Na Day 5 Serum K
Day of 
hyponatremia 
development
Plasma 
Osmo
Volume 
Status
UrineSodi
um
Uric acid 1 Uric acid 5
BUN/ 
Creatinine
HCT 1  HCT 5 Albumin 1 Albumin 5
SIADH/   
CSW
Duration 
of 
hospital 
stay
Outcome
1 48887 79 1 2 3 1 117 144 4.8 1 248.8 3 42 3 4.8 7.45 37.8 41 3.1 3 1 5 2
2 60874 68 1 1 3 2 128 137 4.4 3 265 1 37 2.2 4.7 17.3 35.4 40 3.2 4.6 1 6 1
3 52345 62 1 3 2 1 128 131 6.2 4 268 2 32 3.1 2.9 32 52 44 4.1 3 2 6 1
4 60045 45 1 1 3 1 129 133 3.7 5 267 3 26 6 8.125 38 42 2.5 4.1 1 12 1
5 56678 63 1 1 3 3 126 136 4 9 265 1 29 2 4.9 12.13 32.7 34 4 4.4 1 12 1
6 53835 80 2 1 2 3 127 132 3.7 5 284 14 3 3 18 1
7 54756 79 2 1 2 1 129 133 5 1 274 3 23 3.3 5.2 18 49.2 48 2.1 2.6 1 5 1
8 55714 51 2 1 2 1 127 136 4.4 1 255 1 38 2.1 32.5 33 3.4 3.6 1 4 1
9 52113 61 1 1 2 1 128 134 6 5 269 2 27.3 2.6 2.5 19.3 55.7 50 4.6 3.9 2 130 2
10 53929 75 1 3 3 3 128 3.9 2 248 2 33 3 3.4 21.1 48 33 4.1 3.3 2 8 2
11 62655 70 2 1 2 2 130 136 3.62 2 299 46.5 18.8 3 10 1
12 57361 70 1 1 2 3 129 141 2.8 3 299 3 4 2
13 59149 81 2 1 2 1 126 5.8 1 275 2 25 2.5 37.2 48 5.1 2 1 2
HYPONATREMIC GROUP (n=13) 
xvi 
 
KEY TO MASTER CHART 
S.No.    - Serial Number 
IP No.    - Inpatient Number 
Age    - (in years) 
Sex    - 1- Male 
     2- Female 
Stroke type   - 1-Ischemic stroke 
     2-Intracerebral hemorrhage 
     3-Sub-arachnoid hemorrhage 
Stroke territory  - Vascular territory involved in stroke 
1- Anterior cerebral Artery 
2- Middle cerebral Artery 
3- Posterior cerebral Artery 
Side    - Side of cerebral involvement 
1- Right 
2- Left 
Serum Sodium   - (Units - meq/L) 
Na    - Sodium  
Serum K   - Serum Potassium (Units - meq/L) 
Plasma Osmolality    - (Units- mosm /kg)  
Volume status  - ECF volume 
1- Increased 
2- Decreased 
3- Normal 
Urine sodium  - (units meq/L) 
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Uric Acid   - (Units mg/ dl) 
     Uric acid 1-day 1 value of uric acid 
     Uric acid 5-day 5 value of uric acid 
BUN /Creatinine  - (Units mg/ dl) 
Hct    - Hematocrit (units - %) 
     Hct-1    - day 1 hematocrit 
     Hct -5    - day 5 hematocrit 
Albumin   - (Units g/dl) 
     Albumin 1    -  day 1 albumin 
     Albumin 5    -  day 5 albumin 
SIADH   - Syndrome Of Inappropriate Anti-diuretic  
     Hormone secretion 
CSW    - Cerebral Salt Wasting 
Duration of Hospital stay - (In days) 
SIADH/CSW  - 1-SIADH 
     2-CSW 
Outcome   - 1-Cure 
     2-Death 
 
